Clinitech Laboratory has announced the acquisition of 9,600 equity shares by promoter Jagdish Umakant Nayak through an open market transaction completed on March 30, 2026. This represents the latest in a series of acquisitions by the promoter group, following recent purchases by other promoter group members.

Latest Transaction Details

The share purchase by Jagdish Umakant Nayak, who serves as Promoter & Managing Director, represents the largest single acquisition in the recent series of promoter group investments. The transaction was executed through open market operations and disclosed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011.

Updated Shareholding Pattern

Following this latest acquisition, the promoter group's collective shareholding has increased significantly. The transaction reflects the continued commitment of the promoter group to strengthen their stake in the diagnostic services company.

Recent Promoter Group Activity

This acquisition follows a series of recent transactions by promoter group members, including purchases by Siddhesh Anant Nayak (2,400 shares on March 27, 2026) and an earlier acquisition by Jagdish Umakant Nayak (1,200 shares on March 25, 2026). The combined transactions demonstrate sustained investment by the promoter group.

Promoter Group Structure

The disclosure identifies the complete promoter group structure with Jagdish Umakant Nayak as the primary promoter. The promoter group includes several persons acting in concert (PACs):

• Jagdish Umakant Nayak (Promoter & Managing Director)
• Jyoti Jagdish Nayak
• Ashutosh Jagdish Nayak
• Ananya Jagdish Nayak
• Anant Umakant Nayak
• Siddhesh Anant Nayak
• Eshwari Anant Nayak

Regulatory Compliance

The transaction was properly disclosed to the Bombay Stock Exchange Limited (BSE), where Clinitech Laboratory Limited shares are listed under scrip code 544220. The disclosure fulfills the company's obligations under SEBI regulations for substantial acquisition reporting. The acquired shares carry full voting rights and represent equity participation in the diagnostic laboratory services provider.

Clinitech Laboratory promoter Jagdish Umakant Nayak has acquired additional equity shares of the company through open market purchases, as disclosed in a regulatory filing dated March 20, 2026. The acquisition was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011.

Share Acquisition Details

The promoter acquired a total of 4,800 equity shares through open market transactions conducted over two consecutive days. The acquisition schedule was structured as follows:

Shareholding Pattern Changes

The acquisition resulted in an increase in the promoter group's overall shareholding in Clinitech Laboratory Limited. The shareholding pattern before and after the transaction shows the following changes:

Promoter Group Structure

Jagdish Umakant Nayak serves as the promoter and managing director of the company with DIN 00646672. The promoter group includes several persons acting in concert (PACs):

• Mrs. Jyoti Jagdish Nayak
• Mr. Ashutosh Jagdish Nayak
• Ms. Ananya Jagdish Nayak
• Mr. Anant Umakant Nayak
• Mr. Siddhesh Anant Nayak
• Ms. Eshwari Anant Nayak

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations governing substantial acquisition of shares. The company's shares are listed on the Bombay Stock Exchange Limited (BSE) under the symbol CTLLAB with scrip code 544220. The acquired shares are equity shares carrying voting rights, and no encumbrances or convertible securities were involved in this transaction.

The promoter's PAN number is AAVPN2102P, and the acquisition was conducted through standard open market purchases without any special arrangements or preferential allotments.